[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: Local control and toxicity profile after 24 months

Tumori

Volumn 96, Issue 4, 2010, Pages 613-617

  Alongi, Filippo ^a,b,c   Schipani, Stefano ^a   Gajate, Ana Maria Samanes ^a   Rosso, Alberto ^a   Cozzarini, Cesare ^a   Fiorino, Claudio ^a   Alongi, Pierpaolo ^d   Picchio, Maria ^a   Gianolli, Luigi ^a   Messa, Cristina ^e   Di Muzio, Nadia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^c Unit of Internal Medicine   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Lymph node; Prostate; Relapse; Tomotherapy

Indexed keywords

BICALUTAMIDE; CHOLINE C 11; ESTRAMUSTINE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ALKYLATING AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARBON; CHOLINE; DIAGNOSTIC AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CASE REPORT; COLON ADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; ECHOGRAPHY; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; MALE; PELVIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RECURRENT CANCER; THORAX RADIOGRAPHY; TOMOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; METASTASIS; METHODOLOGY; PATHOLOGY; PELVIS TUMOR; PROSTATE TUMOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CARBON RADIOISOTOPES; CHEMOTHERAPY, ADJUVANT; CHOLINE; ESTRAMUSTINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT OUTCOME;

EID: 77957197894     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600416     Document Type: Article

References (23)

1. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M: Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med, 113: 895-904, 2008.
2. Wagner M, Sokoloff M, Daneshmand S: The role of pelvic lymphadenectomy for prostate cancer - therapeutic? J Urol, 179: 408-413, 2008.
3. Kim BS, Lashkari A, Vongtama R, Lee SP, Parker RG: Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer, 3: 93-97, 2004. (Pubitemid 39403227)
4. Bentzen SM, Ritter MA: The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol, 76: 1-3, 2005.
5. Fiorino C, Alongi F, Broggi S, Cattaneo M, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, Valdagni R, Fazio F, Calandrino R: Physics aspects of prostate tomotherapy: planning optimization and image-guided issues. Acta Oncol, 47: 1309-1316, 2008.
6. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA, 291: 1325-1332, 2004. (Pubitemid 38541647)
7. 11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging, 37: 301-309, 2009.
8. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, DeMatteo RP: Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg, 205: 231-238, 2007. (Pubitemid 47095434)
9. Katz EE, Harding JN 3rd, Brendler C: Return of serum prostate-specific antigen to undetectable level following removal of solitary lymph node metastasis. J Urol, 168: 2546, 2002.
10. Wolff I, Grimm MO, Wirth M: Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent. Urologe A, 47: 1436-1440, 2008.
11. Sakamoto N, Eto M, Ando S: Surgical excision of ametastatic adrenal lesion in a patient with prostatic cancer. Int J Urol, 6: 38-40, 1999. (Pubitemid 30406807)
12. Pruthi RS, Hubbard JS, Kouba E, Wallen E: Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int, 9: 371-373, 2007.
13. Rubin P, Brasacchio R, Katz A: Solitary metastases: illusion versus reality. Semin Radiat Oncol, 16: 120-130, 2006.
14. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H: Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary andmetastatic lung cancers. Int J Radiat Oncol Biol Phys, 56: 126-135, 2003.
15. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M: Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys, 72: 398-403, 2008.
16. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L: Stereotactic body radiation therapy inmultiple organ sites. J Clin Oncol, 25: 947-952, 2007. (Pubitemid 350002860)
17. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P: Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys, 58: 3-10, 2004.
18. Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, Cambria R, Brait L, Possanzini M, Bianchi LC, Vavassori A, Zerini D, Orsi F, de Cobelli O, Orecchia R: Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol, 3: 14-17, 2009.
19. Engels B, Soete G, Tournel K, Bral S, De Coninck P, Verellen D, Storme G: Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat, 8: 353-360, 2009.
20. Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, Valdagni R, Calandrino R, Fazio F: Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 74: 392-398, 2009.
21. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, DiMuzio N: IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol, 93: 207-212, 2009.
22. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A: Long-termresults of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys, 71: 1028-1033, 2008.
23. Yang JC, Abad J, Sherry R: Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol, 16: 131-135, 2006.